AR100772A1 - Métodos para aumentar la inhibición tónica y tratar el insomnio secundario - Google Patents
Métodos para aumentar la inhibición tónica y tratar el insomnio secundarioInfo
- Publication number
- AR100772A1 AR100772A1 ARP150101808A ARP150101808A AR100772A1 AR 100772 A1 AR100772 A1 AR 100772A1 AR P150101808 A ARP150101808 A AR P150101808A AR P150101808 A ARP150101808 A AR P150101808A AR 100772 A1 AR100772 A1 AR 100772A1
- Authority
- AR
- Argentina
- Prior art keywords
- sleep
- increase
- subject
- reduce
- methods
- Prior art date
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title abstract 3
- 230000009478 tonic inhibition Effects 0.000 title abstract 3
- 230000007958 sleep Effects 0.000 abstract 6
- 230000008452 non REM sleep Effects 0.000 abstract 3
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000037046 slow wave activity Effects 0.000 abstract 2
- 230000037322 slow-wave sleep Effects 0.000 abstract 2
- 230000002618 waking effect Effects 0.000 abstract 2
- ZDZDSZQYRBZPNN-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrochloride Chemical compound Cl.C1NCCC2=C1ONC2=O ZDZDSZQYRBZPNN-UHFFFAOYSA-N 0.000 abstract 1
- 208000009575 Angelman syndrome Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004620 sleep latency Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
Métodos para aumentar la inhibición tónica en un sujeto que lo necesita, por ejemplo, un sujeto que padece del síndrome del X Frágil o el síndrome de Angelman. También se describen métodos para tratar el insomnio secundario en un sujeto con una enfermedad o trastorno neurodegenerativo. Los métodos pueden incluir administrar al sujeto una cantidad eficaz de 4,5,6,7-tetrahidroisoxazol(5,4-c)piridin-3-ol (THIP) o un derivado del mismo, o una sal farmacéuticamente aceptable del mismo, para aumentar la inhibición tónica en las neuronas de un sujeto; aumentar el sueño de ondas lentas (SWS) y/o la actividad de ondas lentas (SWA), normalizar la arquitectura del sueño, reducir el insomnio secundario, aumentar el sueño de movimiento ocular no rápido (NREM), aumentar el sueño, mejorar la actividad delta durante el NREM, aumentar o mejorar las horas totales de sueño (TST), aumentar o mejorar la eficiencia del sueño, reducir las horas totales de vigilia (TAA), reducir la cantidad de despertadas (NWA), reducir la latencia al sueño persistente (LPS) o reducir el despertar tras el inicio del sueño (WASO), en el sujeto, o cualquiera de sus combinaciones. Reivindicación 22: El método de cualquiera de las reivindicaciones 1 - 21, caracterizado porque la composición farmacéutica se administra por vía transdérmica. Reivindicación 26: El método de cualquiera de las reivindicaciones 1 - 24, caracterizado porque la composición se administra al sujeto por vía intravenosa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462008939P | 2014-06-06 | 2014-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR100772A1 true AR100772A1 (es) | 2016-11-02 |
Family
ID=54767324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150101808A AR100772A1 (es) | 2014-06-06 | 2015-06-05 | Métodos para aumentar la inhibición tónica y tratar el insomnio secundario |
Country Status (19)
Country | Link |
---|---|
US (10) | US20150352085A1 (es) |
EP (3) | EP3151832B1 (es) |
JP (4) | JP2017516868A (es) |
AR (1) | AR100772A1 (es) |
AU (4) | AU2015269667B2 (es) |
CA (1) | CA2950845C (es) |
CY (2) | CY1124368T1 (es) |
DK (2) | DK3151832T3 (es) |
ES (2) | ES2875742T3 (es) |
HR (2) | HRP20210901T1 (es) |
HU (2) | HUE055400T2 (es) |
IL (2) | IL249287B (es) |
LT (2) | LT3372229T (es) |
MX (2) | MX2016016136A (es) |
PL (2) | PL3372229T3 (es) |
PT (2) | PT3151832T (es) |
RS (2) | RS62006B1 (es) |
SI (2) | SI3372229T1 (es) |
WO (1) | WO2015187851A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016016136A (es) | 2014-06-06 | 2017-07-05 | Ovid Therapeutics Inc | Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario. |
US10080898B2 (en) * | 2015-05-29 | 2018-09-25 | Medtronic, Inc. | Simultaneous physiological sensing and stimulation with saturation detection |
US10434308B2 (en) | 2015-05-29 | 2019-10-08 | Medtronic, Inc. | Impedance matching and electrode conditioning in patient interface systems |
US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
MX2018000745A (es) * | 2015-07-17 | 2018-08-15 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
WO2018017639A1 (en) * | 2016-07-19 | 2018-01-25 | Georgia State University Research Foundation | Methods for treating rett syndrome |
CA3032686A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Use of ganaxolone for treating status epilepticus in a subject |
EP3528807A4 (en) * | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN |
US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
JP2020529440A (ja) | 2017-08-04 | 2020-10-08 | オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
US11181384B2 (en) * | 2018-07-23 | 2021-11-23 | Waymo Llc | Verifying map data using challenge questions |
WO2020061410A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
KR20210110585A (ko) * | 2018-11-21 | 2021-09-08 | 썰테고 테라퓨틱스 아이엔씨. | 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌 |
US11690829B2 (en) | 2018-12-17 | 2023-07-04 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
AU2020313930A1 (en) * | 2019-07-15 | 2022-02-03 | Ovid Therapeutics Inc. | Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
EP4051272A4 (en) * | 2019-12-18 | 2023-01-04 | Ovid Therapeutics Inc. | GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME |
CA3182508A1 (en) | 2020-05-20 | 2021-11-25 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
DE19526864A1 (de) | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
US20050137222A1 (en) * | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
BRPI0509210A (pt) | 2004-04-02 | 2007-08-28 | Lundbeck & Co As H | uso de gaboxadol, e, métodos para tratar função respiratória enfraquecida, e apnéia do sono |
DE102005020882A1 (de) * | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
US20110046090A1 (en) * | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
JP5909750B2 (ja) | 2007-11-13 | 2016-04-27 | マリンクロット アイピー | 低用量静脈内アセトアミノフェン |
CA2732636A1 (en) * | 2008-09-01 | 2009-05-07 | H. Lundbeck A/S | Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat |
MX2016016136A (es) | 2014-06-06 | 2017-07-05 | Ovid Therapeutics Inc | Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario. |
MX2018000745A (es) * | 2015-07-17 | 2018-08-15 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
-
2015
- 2015-06-03 MX MX2016016136A patent/MX2016016136A/es unknown
- 2015-06-03 SI SI201531620T patent/SI3372229T1/sl unknown
- 2015-06-03 JP JP2017516256A patent/JP2017516868A/ja not_active Withdrawn
- 2015-06-03 EP EP15803364.7A patent/EP3151832B1/en active Active
- 2015-06-03 PT PT158033647T patent/PT3151832T/pt unknown
- 2015-06-03 PT PT181692112T patent/PT3372229T/pt unknown
- 2015-06-03 US US14/729,910 patent/US20150352085A1/en not_active Abandoned
- 2015-06-03 PL PL18169211T patent/PL3372229T3/pl unknown
- 2015-06-03 PL PL15803364T patent/PL3151832T3/pl unknown
- 2015-06-03 EP EP18169211.2A patent/EP3372229B1/en active Active
- 2015-06-03 AU AU2015269667A patent/AU2015269667B2/en active Active
- 2015-06-03 ES ES18169211T patent/ES2875742T3/es active Active
- 2015-06-03 CA CA2950845A patent/CA2950845C/en active Active
- 2015-06-03 HU HUE18169211A patent/HUE055400T2/hu unknown
- 2015-06-03 HU HUE15803364A patent/HUE055155T2/hu unknown
- 2015-06-03 SI SI201531616T patent/SI3151832T1/sl unknown
- 2015-06-03 MX MX2020012404A patent/MX2020012404A/es unknown
- 2015-06-03 RS RS20210711A patent/RS62006B1/sr unknown
- 2015-06-03 DK DK15803364.7T patent/DK3151832T3/da active
- 2015-06-03 DK DK18169211.2T patent/DK3372229T3/da active
- 2015-06-03 WO PCT/US2015/034018 patent/WO2015187851A1/en active Application Filing
- 2015-06-03 LT LTEP18169211.2T patent/LT3372229T/lt unknown
- 2015-06-03 LT LTEP15803364.7T patent/LT3151832T/lt unknown
- 2015-06-03 RS RS20210718A patent/RS62007B1/sr unknown
- 2015-06-03 ES ES15803364T patent/ES2876350T3/es active Active
- 2015-06-03 EP EP20204995.3A patent/EP3795156A1/en active Pending
- 2015-06-05 AR ARP150101808A patent/AR100772A1/es not_active Application Discontinuation
- 2015-10-19 US US14/886,764 patent/US9339495B2/en active Active
-
2016
- 2016-04-19 US US15/132,641 patent/US9446028B2/en active Active
- 2016-11-04 US US15/343,690 patent/US9744159B2/en active Active
- 2016-11-29 IL IL249287A patent/IL249287B/en active IP Right Grant
- 2016-12-12 US US15/375,735 patent/US9801864B2/en active Active
-
2017
- 2017-06-09 US US15/618,736 patent/US20170273956A1/en not_active Abandoned
- 2017-09-27 US US15/716,726 patent/US20180015076A1/en not_active Abandoned
-
2018
- 2018-06-29 US US16/023,282 patent/US11278529B2/en active Active
-
2019
- 2019-08-27 IL IL268960A patent/IL268960B/en active IP Right Grant
- 2019-11-29 JP JP2019217208A patent/JP2020063264A/ja not_active Withdrawn
-
2020
- 2020-08-11 AU AU2020217342A patent/AU2020217342B2/en active Active
-
2021
- 2021-06-07 HR HRP20210901TT patent/HRP20210901T1/hr unknown
- 2021-06-07 HR HRP20210902TT patent/HRP20210902T1/hr unknown
- 2021-06-10 CY CY20211100510T patent/CY1124368T1/el unknown
- 2021-06-10 CY CY20211100509T patent/CY1124366T1/el unknown
- 2021-07-15 JP JP2021116935A patent/JP2021178836A/ja active Pending
- 2021-09-30 US US17/490,650 patent/US20220016091A1/en active Pending
-
2022
- 2022-01-07 AU AU2022200085A patent/AU2022200085A1/en not_active Abandoned
- 2022-08-08 US US17/882,939 patent/US20230051859A1/en active Pending
-
2023
- 2023-05-30 JP JP2023088456A patent/JP2023123442A/ja active Pending
-
2024
- 2024-04-22 AU AU2024202604A patent/AU2024202604A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR100772A1 (es) | Métodos para aumentar la inhibición tónica y tratar el insomnio secundario | |
EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
PE20170673A1 (es) | Terapia de combinacion para tratar una paramixovirus | |
EA201101507A1 (ru) | Способы лечения солидных опухолей | |
PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
EA201490495A1 (ru) | Новые легкоразрушающиеся ингибиторы rock | |
CL2018001881A1 (es) | Compuestos y composiciones para el tratamiento de la criptoporidiosis | |
CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
CL2022002855A1 (es) | Uso médico de daridorexant | |
CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
MX2020004667A (es) | Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas. | |
RU2016103098A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii | |
BR112015009504A2 (pt) | inibidores de rock |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |